These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 11835461

  • 1. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 2. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 3. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 4. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 5. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Stefani A, Stanzione P, Bassi A, Mazzone P, Vangelista T, Bernardi G.
    J Neural Transm (Vienna); 1997 Nov; 104(8-9):895-904. PubMed ID: 9451721
    [Abstract] [Full Text] [Related]

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 7. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 8. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR, Mata M.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W, Wenning GK.
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [Abstract] [Full Text] [Related]

  • 10. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O.
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [Abstract] [Full Text] [Related]

  • 11. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P, Konitsiotis S, Antonini A.
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Feb; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 13. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
    Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C.
    Clin Neuropharmacol; 2003 Feb; 26(3):146-50. PubMed ID: 12782917
    [Abstract] [Full Text] [Related]

  • 14. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ, Kulisevsky J.
    Rev Neurol; 2012 Feb; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [Abstract] [Full Text] [Related]

  • 15. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
    Jansen EN, van Laar T.
    Ned Tijdschr Geneeskd; 1990 May 05; 134(18):889-91. PubMed ID: 2345577
    [No Abstract] [Full Text] [Related]

  • 16. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J, Ibáñez R, Gudín M, Hernández A.
    Neurologia; 2003 Apr 05; 18(3):162-5. PubMed ID: 12677484
    [Abstract] [Full Text] [Related]

  • 17. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W, Stacy M.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [Abstract] [Full Text] [Related]

  • 18. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    Espay AJ, Lang AE.
    JAMA Neurol; 2017 Jun 01; 74(6):633-634. PubMed ID: 28459962
    [No Abstract] [Full Text] [Related]

  • 19. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T.
    Expert Opin Pharmacother; 2020 Oct 01; 21(14):1659-1665. PubMed ID: 32640853
    [Abstract] [Full Text] [Related]

  • 20. Rapid treatment of "wearing off" in Parkinson's disease.
    Swope DM.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.